BRAF and metastatic melanoma: In patients with BRAF-mutated metastatic melanoma treated with BRAF and MEK inhibitors, certain gene signatures have been identified as prognostic (Table S4)10,16—the ‘immune’ gene signature being favourable and the ‘cell cycle’ being unfavourable.